Literature DB >> 30377040

Mesenchymal stromal cell secretory factors induce sustained improvements in islet function pre- and post-transplantation.

Chloe L Rackham1, Stefan Amisten2, Shanta J Persaud2, Aileen J F King2, Peter M Jones3.   

Abstract

BACKGROUND AIMS: Mesenchymal stromal cells (MSCs) enhance islet function both in vitro and in vivo, at least in part by secreting ligands that activate islet G-protein coupled receptors (GPCRs). We assessed whether pre-treatment with a defined "cocktail" of MSC-secreted GPCR ligands enhances islet functional survival in vitro and improves the outcomes of islet transplantation in an experimental model of diabetes.
METHODS: Isolated islets were cultured for 48 h with ANXA1, SDF-1 or C3a, alone or in combination. Glucose-stimulated insulin secretion (GSIS) and cytokine-induced apoptosis were measured immediately after the 48 h culture period and at 24 h or 72 h following removal of the ligands from the culture media. Islets were syngeneically transplanted underneath the kidney capsule of streptozotocin-induced diabetic C57BL/6 mice and blood glucose levels monitored for 28 days.
RESULTS: Pre-culturing islets with a cocktail of ANXA1/SDF-1/C3a potentiated GSIS and protected islet cells from cytokine-induced apoptosis in vitro. These effects were maintained for up to 72 h after the removal of the factors from the culture medium, suggesting a sustained protection of islet graft functional survival during the immediate post-transplantation period. Islets pre-treated with the cocktail of MSC secretory factors were more effective in reducing blood glucose in diabetic mice, consistent with their improved functional survival in vivo. DISCUSSION: Pre-culturing islets with a cocktail of MSC secretory products offers a well-defined, cell-free approach to improve clinical islet transplantation outcomes while avoiding many of the safety, regulatory and logistical hurdles of incorporating MSCs into transplantation protocols. Crown
Copyright © 2018. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  diabetes; islet transplantation; mesenchymal stromal cells; secretome

Mesh:

Substances:

Year:  2018        PMID: 30377040     DOI: 10.1016/j.jcyt.2018.07.007

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  9 in total

Review 1.  Annexin Animal Models-From Fundamental Principles to Translational Research.

Authors:  Thomas Grewal; Carles Rentero; Carlos Enrich; Mohamed Wahba; Carsten A Raabe; Ursula Rescher
Journal:  Int J Mol Sci       Date:  2021-03-26       Impact factor: 5.923

2.  BMSCs overexpressed ISL1 reduces the apoptosis of islet cells through ANLN carrying exosome, INHBA, and caffeine.

Authors:  Ying Wang; Jiang-Wei Zhang; Jing-Wen Wang; Jia-Le Wang; Shu-Cong Zhang; Rui-Yang Ma; Jing Zhang; Yang Li; Pei-Jun Liu; Wu-Jun Xue; Jin Zheng; Xiao-Ming Ding
Journal:  Cell Mol Life Sci       Date:  2022-10-03       Impact factor: 9.207

3.  Characterization of the Effects of Mesenchymal Stromal Cells on Mouse and Human Islet Function.

Authors:  Ahmed A Arzouni; Andreia Vargas-Seymour; Paramjeet K Dhadda; Chloe L Rackham; Guo-Cai Huang; Pratik Choudhary; Aileen J F King; Peter M Jones
Journal:  Stem Cells Transl Med       Date:  2019-05-08       Impact factor: 6.940

4.  Optimizing beta cell function through mesenchymal stromal cell-mediated mitochondria transfer.

Authors:  Chloe L Rackham; Ella L Hubber; Anna Czajka; Afshan N Malik; Aileen J F King; Peter M Jones
Journal:  Stem Cells       Date:  2020-01-08       Impact factor: 6.277

Review 5.  Mesenchymal Stem Cells: A Trump Card for the Treatment of Diabetes?

Authors:  Elisabetta Donzelli; Arianna Scuteri
Journal:  Biomedicines       Date:  2020-05-06

Review 6.  Towards a Functional Cure for Diabetes Using Stem Cell-Derived Beta Cells: Are We There Yet?

Authors:  Stephanie Bourgeois; Toshiaki Sawatani; Annelore Van Mulders; Nico De Leu; Yves Heremans; Harry Heimberg; Miriam Cnop; Willem Staels
Journal:  Cells       Date:  2021-01-19       Impact factor: 6.600

7.  Human Hemangioblast-Derived Mesenchymal Stem Cells Promote Islet Engraftment in a Minimal Islet Mass Transplantation Model in Mice.

Authors:  Suzanne Bertera; Michael F Knoll; Carmela Knoll; Hidetaka Hara; Erin A Kimbrel; Nickolas A Kouris; Robert Lanza; Brett E Philips; Yesica Garciafigueroa; Nick Giannoukakis; David K C Cooper; Massimo Trucco; Rita Bottino
Journal:  Front Med (Lausanne)       Date:  2021-04-15

Review 8.  Protecting islet functional viability using mesenchymal stromal cells.

Authors:  Ella L Hubber; Chloe L Rackham; Peter M Jones
Journal:  Stem Cells Transl Med       Date:  2021-02-05       Impact factor: 6.940

Review 9.  The Multi-Therapeutic Role of MSCs in Diabetic Nephropathy.

Authors:  Yi Wang; Su-Kang Shan; Bei Guo; Fuxingzi Li; Ming-Hui Zheng; Li-Min Lei; Qiu-Shuang Xu; Muhammad Hasnain Ehsan Ullah; Feng Xu; Xiao Lin; Ling-Qing Yuan
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-07       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.